ULFS 49 CL, a prototype of a novel pharmacological concept

  • Christian Lillie
Conference paper


In patients with stable angina pectoris, ischemic attacks during exercise or other stress are caused by an imbalance between myocardial oxygen demand and oxygen supply. Current anti-ischemic drug therapy is aimed to extend exercise tolerance by an improvement of the O2-demand/supply ratio. Antianginal drugs have been traditionally categorized as vasodilators mainly increasing O2-supply (e.g., calcium-channel blockers, nitrates) and heart-rate-reducing drugs (e.g., β-adrenoceptor blockers), or combinations thereof (e.g., verapamil or diltiazem-like calcium-channel blockers). The conventional view of the mechanism of action of β-adrenoceptor blockers is relief of ischemia by a decrease of myocardial O2-demand during exercise due to reductions of heart rate and contractility. However, the benefit of the negative inotropic effect of β-adrenoceptor blockers remains in dispute. The attenuation of exercise-induced tachycardia and the preservation of an adequate diastolic perfusion time was often suggested as the only therapeutic principle of β-adrenoceptor blockers.


Sinoatrial Node Sinus Rate Pacemaker Current Positive Chronotropic Effect Maximum Diastolic Potential 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown HF (1982) Electrophysiology of the sinoatrial node. Physiol Rev 62: 505–530PubMedGoogle Scholar
  2. 2.
    Dämmgen J, Kadatz R, Diederen W (1981) Cardiovascular actions of 5,6-dimethoxy-2-[3[[α-(3,4-dimethoxy)-phenylethyl]-methylamino]propyl]phtalimidine (AQ-A 39), a specific bradycardic agent. Arzneim Forsch 31: 666–670Google Scholar
  3. 3.
    Dämmgen JW, Lamping KA, Gross GJ (1985) Actions of two new bradycardic agents, AQ-AH 208 and ULFS 49 CL, on ischemic myocardial perfusion and function. J Cardiovasc Pharmacol 7: 71–79PubMedCrossRefGoogle Scholar
  4. 4.
    Denyer JC, Brown HF (1990) Pacemaking in rabbit isolated sino-atrial node cells during Cs+ block of the hyperpolarization-activated current if. J Physiol (London) 429: 401–409Google Scholar
  5. 5.
    Di Francesco D, Ferroni A, Mazzanti M, Tromba C (1986) Properties of the hyperpolarizing- activated current (if) in cells isolated from the rabbit sino-atrial node. J Physiol (London) 377: 61–88Google Scholar
  6. 6.
    Doerr Th, Trautwein W (1990) On the mechanism of the “specific bradycardic action” of the verapamil derivative ULFS 49 CL. Naunyn Schmiedeberg’s Arch Pharmacol 341: 331–340CrossRefGoogle Scholar
  7. 7.
    Gruber R, Lumper G, Zilberszac A, Heistracher P (1983) Effects of 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methyhmino]propyl]-2H-3-benzazepin- 2-on hydrochloride (ULFS 49 CL) on the action potential of the guinea-pig heart. Naunyn Schmiedeberg’s Arch Pharmacol 324: R 32Google Scholar
  8. 8.
    Guth BD, Heusch G, Seitelberger R, Ross J Jr (1987) Elimination of exercise-induced myocardial dysfunction by a bradycardic agent in dogs with coronary artery stenosis. Circulation 75: 661–669PubMedCrossRefGoogle Scholar
  9. 9.
    Hagiwara N, Irisaawa H, Kameyama M (1988) Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol (London) 395: 233–253Google Scholar
  10. 10.
    Harron DWG, Shanks RG (1985) Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine. Eur Heart J 6: 722–729PubMedGoogle Scholar
  11. 11.
    Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, Ross J Jr (1989). Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on ULFS 49 CL in swine. Circulation 80: 983–993PubMedCrossRefGoogle Scholar
  12. 12.
    Kobinger W (1989) Specific bradycardic agents. In: Vaughan Williams EM, Campbell TJ (eds) Handbook of experimental pharmacology, Vol. 89. Springer-Verlag, Berlin Heidelberg, pp 423–452Google Scholar
  13. 13.
    Kobinger W, Lillie C (1981) AQ-A 39 (5,6-dimethoxy-2[3[[α-(3,4-dimethoxy)phenyle- thyl]methylamino]propyl]phtalimidine), a specific bradycadic agent with direct action on the heart. Eur J Pharmacol 72: 153–164PubMedCrossRefGoogle Scholar
  14. 14.
    Kobinger W, Lillie C (1984) Alinidine. In: Scriabine A (ed) New drugs annual: Cardiovascular drugs, vol 2. Raven Press, New York, pp 193–210Google Scholar
  15. 15.
    Kobinger W, Lillie C (1984) Cardiovascular characterization of ULFS 49 CL, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new “specific bradycardic agent”. Eur J Pharmacol 104: 9–18PubMedCrossRefGoogle Scholar
  16. 16.
    Kobinger W, Lillie C (1987) Specific bradycardic agents—a novel pharmacological class? Eur Heart J 8 ( Suppl. L): 7–15Google Scholar
  17. 17.
    Kobinger W, Lillie C (1988) Falipamil (AQ-A 39) and ULFS 49 CL. Cardiovascular Drug Reviews 6: 35–53CrossRefGoogle Scholar
  18. 18.
    Kobinger W, Lillie C, Pichler L (1979) Cardiovascular actions of N-allyl-clonidine (ST 567), a substance with specific bradycardic action. Eur J Pharmacol 58: 141–150PubMedCrossRefGoogle Scholar
  19. 19.
    Krumpl G, Schneider W, Raberger G (1986) Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents? Naunyn Schmiedeberg’s Arch Pharmacol 334: 540–543PubMedCrossRefGoogle Scholar
  20. 20.
    Krumpl G, Winkler M, Schneider W, Raberger G (1988) Comparison of the haemodynamic effects of the selective bradycardic agent ULFS 49 CL, with those of propranolol during treadmill exercise in dogs. Br J Pharmacol 94: 55–64PubMedGoogle Scholar
  21. 21.
    Lillie C, Kobinger W (1983) Cardiovascular actions of ULFS 49 CL, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new “specific bradycardic agent”. Naunyn Schmiedeberg’s Arch Pharamcol 324: R 33Google Scholar
  22. 22.
    Lillie C, Kobinger W (1986) Investigations into the bradycardic effects of ULFS 49 CL (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyhenyl)ethyl]methylimino]propyl]- 2H-3-benzazepin-2-on hydrochloride) in isolated guinea pig atria. J Cardiovasc Pharmacol 8: 791–797PubMedGoogle Scholar
  23. 23.
    Opt Hof T, Bouman LN (1988) personal communication. In: Kobinger W, Lillie C. Falipamil (AQ-A 39) and ULFS 49 CL. Cardiovascular Drug Reviews 6: 35–53CrossRefGoogle Scholar
  24. 24.
    Raberger G, Krumpl G, Schneider W (1987) Effects of the bradycardic agent ULFS 49 CL on exercise-induced regional contractile dysfunction in dogs. Int J Cardiol 14: 343–354PubMedCrossRefGoogle Scholar
  25. 25.
    Reiffen M, Eberlein, W, Müller P, Psiorz M, Noll K, Heider J, Lillie C, Kobinger W, Luger P (1990) Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties. J Med Chem 33: 1496–1504PubMedCrossRefGoogle Scholar
  26. 26.
    Riley DC, Gross GJ, Kampine KP, Warltier DC (1987) Specific bradycardic agents, a new therapeutic modality for anaesthesiology: hemodynamic effects of ULFS 49 CL and propranolol in conscious and isoflurane-anesthetized dogs. Anaesthesiology 67: 707–716CrossRefGoogle Scholar
  27. 27.
    Ross J Jr (1989) Mechanisms of regional ischemia and antianginal drug action during exercise. Prog Cardiov Dis 31: 455–466CrossRefGoogle Scholar
  28. 28.
    Tytgat J, Van Bogaert PP, Vereecke J, Carmeliet E (1990) Sensitivity of ventricular L-type Ca Channels to the bradycardic agents AQ-A 39, ULFS 49 CL and DK-AH 3. In: Vereeke J, Van Bogaert PP, Verdonck F (eds) Ionic currents and Ischemia. Leuven University Press, pp 276–278Google Scholar
  29. 29.
    Van Bogaert PP, Goethals M (1987) Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules. Eur Heart J 8 ( Suppl. L): 35–42Google Scholar
  30. 30.
    Van Bogaert PP, Goethals M, Simoens C (1990) Use- and frequency-dependent blockade by ULFS 49 CL of the if pacemaker current in sheep cardiac Purkinje fibres. Eur. J Pharmacol 187: 241–256PubMedCrossRefGoogle Scholar
  31. 31.
    Van Ginneken ACG, Bouman LN, Jongsma HJ, Duivenvoorden JJ, Opt Hof T, Giles WR (1987) Alinidine as a model of the mode of action of specific bradycardic agents on SA node activity. Eur Heart J 8 ( Suppl. L): 25–33PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1991

Authors and Affiliations

  • Christian Lillie
    • 1
  1. 1.Bender+Co Ges mbH, Research and DevelopmentViennaAustria

Personalised recommendations